Human IFN-Lambda 2, Human Cell Expressed
Recombinant Human IFN-Lambda 2 protein (Human IL-28A) expressed in human cells (HCE)
$310.00
Product Info
Bioactivity Measured in cytopathic effect inhibition assay on human lung carcinoma cell line A549 with encephalomyocarditis virus (EMCV), EC50 ~1 U/ml
Specifications
| Formulation | Supplied frozen in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) |
|---|---|
| Molecular Weight | 19.8 kDa |
| Source | Recombinant DNA expressed in human cells |
| Purity | Greater than 95% as determined by ion exchange, hydrophobic interaction and/or size exclusion chromatography Endotoxin level < 1 EU/μg |
| Storage | For retention of full activity store at -70°C or below and avoid repeated freeze/thaw cycles |
| Synonyms | Hu-IL-28A; Hu-IFN-λ2 |
| Accession Number | NP_742150.1 |
Tech Info & Data
Background
IFN-Lambda 1 (IL-29), IFN-Lambda 2 (IL-28A) and IFN-Lambda 3 (IL-28B) are recently identified members of the IL-10 family which have antiviral activity similar to type I interferons. They mediate this activity through a heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λ R1). Engagement of this receptor leads to Jak-STAT signaling and gene expression. Many of the effects of interferon lambda on cells overlap that of Type I interferon. Unlike the type interferon receptor which is found on virtually all cells, the type III receptor is limited in its expression. Interferon lambda 1 encodes a 181 amino acid mature protein which is 67% and 69% identical with interferon lambda 2 and interferon lambda 3, respectively.
Citations
1 Citation
- Zhang, Q., et al.,(2022), "Autoantibodies against type I IFNs in patients with critical influenza pneumonia", J. Exp. Med. 219(11):e20220514, DOI: 10.1084/jem.20220514 (link)
References
- Donnelly, RP, et al. (2010). Interferon-lambda: A New Addition to an Old Family. Journal of Interferon & Cytokine Research, 9 pgs. PMID: 20712453. (link)
- Vilcek, J., 2003, Nature Immunol. 4:8 - 9.
- Sheppard, P. et al., 2003, Nature Immunol. 4:63 - 68.
- Kotenko, S.V. et al., 2003, Nature Immunol. 4:69 - 77.